PriceTargets.com logo

Diaceutics - DXRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 160
  • Forecasted Upside: 25.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 128 As of 01/2/2025 07:21 AM ET
▲ +2.5 (1.99%)

This chart shows the closing price for DXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Diaceutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXRX

Analyst Price Target is GBX 160
▲ +25.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Diaceutics in the last 3 months. The average price target is GBX 160, with a high forecast of GBX 160 and a low forecast of GBX 160. The average price target represents a 25.00% upside from the last price of GBX 128.

This chart shows the closing price for DXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Diaceutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
12/17/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
12/5/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
9/17/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
8/20/2024Canaccord Genuity GroupReiterated RatingBuyGBX 160
5/21/2024Canaccord Genuity GroupReiterated RatingBuyGBX 150
3/21/2024Canaccord Genuity GroupReiterated RatingBuyGBX 150
9/26/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
7/25/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
6/5/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
4/17/2023Canaccord Genuity GroupReiterated RatingBuyGBX 150
(Data available from 1/2/2020 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Diaceutics logo
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Read More

Today's Range

Now: GBX 128
Low: 123
High: 128

50 Day Range

MA: GBX 120.33
Low: 115
High: 127

52 Week Range

Now: GBX 128
Low: 84.50
High: 136

Volume

34 shs

Average Volume

106,005 shs

Market Capitalization

£108.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Diaceutics?

The following equities research analysts have issued reports on Diaceutics in the last year: Canaccord Genuity Group Inc..
View the latest analyst ratings for DXRX.

What is the current price target for Diaceutics?

0 Wall Street analysts have set twelve-month price targets for Diaceutics in the last year. Their average twelve-month price target is GBX 160, suggesting a possible upside of 25.0%. Canaccord Genuity Group Inc. has the highest price target set, predicting DXRX will reach GBX 160 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of GBX 160 for Diaceutics in the next year.
View the latest price targets for DXRX.

What is the current consensus analyst rating for Diaceutics?

Diaceutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXRX will outperform the market and that investors should add to their positions of Diaceutics.
View the latest ratings for DXRX.

What other companies compete with Diaceutics?

Other companies that are similar to Diaceutics include ANGLE, Yourgene Health, Abingdon Health, genedrive and Proteome Sciences. Learn More about companies similar to Diaceutics.